Ziopharm Oncology Inc. (NASDAQ:ZIOP) was the recipient of a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 40,806,484 shares, a growth of 6.7% from the October 14th total of 38,245,816 shares. Currently, 34.6% of the company’s shares are short sold. Based on an average daily volume of 1,744,866 shares, the days-to-cover ratio is currently 23.4 days.

Ziopharm Oncology (NASDAQ:ZIOP) opened at 7.60 on Wednesday. The firm has a 50-day moving average price of $5.70 and a 200-day moving average price of $5.88. Ziopharm Oncology has a 12-month low of $4.45 and a 12-month high of $13.74. The company’s market cap is $991.77 million.

Ziopharm Oncology (NASDAQ:ZIOP) last issued its earnings results on Wednesday, November 9th. The biotechnology company reported ($0.11) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.11). The business earned $1.60 million during the quarter, compared to analyst estimates of $1.45 million. Ziopharm Oncology had a negative return on equity of 364.49% and a negative net margin of 2,276.89%. Ziopharm Oncology’s revenue was down 15.8% on a year-over-year basis. During the same period in the previous year, the company posted ($0.14) EPS. On average, equities research analysts forecast that Ziopharm Oncology will post ($1.32) earnings per share for the current fiscal year.

A number of large investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in shares of Ziopharm Oncology by 2.3% in the second quarter. Vanguard Group Inc. now owns 6,726,316 shares of the biotechnology company’s stock worth $36,928,000 after buying an additional 154,404 shares during the period. State Street Corp raised its stake in shares of Ziopharm Oncology by 9.5% in the second quarter. State Street Corp now owns 4,653,446 shares of the biotechnology company’s stock worth $25,546,000 after buying an additional 402,312 shares during the period. BlackRock Institutional Trust Company N.A. raised its stake in shares of Ziopharm Oncology by 1.4% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 3,105,497 shares of the biotechnology company’s stock worth $17,484,000 after buying an additional 43,867 shares during the period. BlackRock Fund Advisors raised its stake in shares of Ziopharm Oncology by 6.8% in the third quarter. BlackRock Fund Advisors now owns 3,083,249 shares of the biotechnology company’s stock worth $17,359,000 after buying an additional 196,683 shares during the period. Finally, FMR LLC purchased a new stake in shares of Ziopharm Oncology during the second quarter worth $10,732,000. 44.07% of the stock is owned by institutional investors and hedge funds.

Several analysts have weighed in on ZIOP shares. Zacks Investment Research upgraded Ziopharm Oncology from a “hold” rating to a “buy” rating and set a $6.50 price objective for the company in a research report on Tuesday, August 16th. Griffin Securities restated a “buy” rating and set a $21.00 target price on shares of Ziopharm Oncology in a report on Monday, August 15th. Finally, Wells Fargo & Co. upgraded Ziopharm Oncology from an “underperform” rating to a “market perform” rating in a report on Wednesday, August 10th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $9.75.

About Ziopharm Oncology

ZIOPHARM Oncology, Inc is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.

5 Day Chart for NASDAQ:ZIOP

Receive News & Stock Ratings for Ziopharm Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ziopharm Oncology Inc. and related stocks with our FREE daily email newsletter.